ABBV-744

Based on 19 reference(s) in Google Scholar 8 10 19

Axon 3956

CAS [2138861-99-9]

MF C28H30FN3O4
MW 491.55

  • Purity: 99%
  • Soluble in DMSO

ABBV-744

Description

ABBV-744 is an orally available first-in-class highly BDII (Bromodomain II)-selective (>100 X selectivity over BDI) BET bromodomain inhibitor, currently is being investigated to treat AML and metastic castration-resistant prostate cancer.

KEYWORDS: ABBV-744 |  BDII selective BET bromodomain inhibitor | ABBV744 | ABBV 744 | CT-ABBV744 | CAS [2138861-99-9] | Histone | BET (BRD) | Inhibitor | Proteins | BDII

First-in-class highly BDII (Bromodomain II)-selective BET bromodomain inhibitor

Chemical name

N-Ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

Source information

Sold in collaboration with Chemietek

Parent CAS No.

[2138861-99-9]

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...